The outcome of cancer patients after cytotoxic chemotherapy is strongly influenced by a
multifunctional cellular system termed multidrug resistance (MDR)(1). In spite of recent …

Technetium-99m sestamibi is a transport substrate recognised by the multidrug-resistant P-
glycoprotein (Pgp). To test whether 99m Tc-sestamibi efflux is enhanced in breast …

Sestamibi is known to be a substrate for P-glycoprotein, the membrane transporter which
confers multi-drug resistance by pumping certain chemotherapeutic agents out of tumour …

Multidrug resistance (MDR) due to expression of a membrane-associated permeability
glycoprotein (P-glycoprotein [Pgp]) prevents successful cytotoxic chemotherapy for breast …

Early diagnosis of multidrug-resistance (MDR) development is extremely important for the
judicious choice of treatment protocols in breast cancer chemotherapy. In this study, the …

The most well-characterized mechanism of multidrug resistance (MDR) involves P-
glycoprotein (Pgp), a transmembrane protein acting as an ATP-dependent drug efflux pump …

The aim of this preliminary study was to evaluate retrospectively sestamibi scintigraphy in
relation to the presence of the 170-kDa P-glycoprotein (Pgp), which represents an …

BACKGROUND: 99mTc-sestamibi (MIBI) and 99mTc-tetrofosmin (TF) are avid transport
substrates recognized by the multidrug resistance (MDR) P-glycoprotein (Pgp). This study …

Resistance to doxorubicin based chemotherapy is a major therapeutic problem limiting
advanced breast cancer treatment. 99m Tc hexakis-2-methoxyisobutylisonitrile (99m Tc …

Various mechanisms are involved in multidrug resistance (MDR) for chemotherapeutic
drugs, such as the drug efflux pumps, P-glycoprotein (Pgp) and multidrug resistance …